Omeros (OMER) Return on Capital Employed (2011 - 2026)
Omeros (OMER) reported Return on Capital Employed of 42.7% for Q1 2026, up 5151.0% on a YoY basis from 0.81% in Q1 2025, and up 38.23% sequentially from 69.14% in Q4 2025.
Omeros (OMER) Return on Capital Employed (2011 - 2026) Analysis & Trends
Omeros (OMER) has 16 years of Return on Capital Employed data on file, last reported at 42.7% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 5151.0% year-over-year to 42.7%; the trailing twelve-month figure through Mar 2026 stood at 42.7% (up 5151.0% YoY), and the FY2025 full-year result was 54.99%, up 1229.0% from the prior year.
- Return on Capital Employed grew to 42.7% in Q1 2026, from 69.14% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 37.6% in Q1 2023 to a low of 113.07% in Q3 2025.
- A 5-year average of 59.69% and a median of 48.12% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 13376 bps in 2022 and slumped 5098 bps in 2025, its largest moves.
- Tracing OMER's Return on Capital Employed over 5 years: stood at 42.12% in 2022, then slipped by 2 bps to 43.03% in 2023, then tumbled by 80 bps to 77.41% in 2024, then grew by 11 bps to 69.14% in 2025, then jumped by 38 bps to 42.7% in 2026.
- Business Quant data shows OMER's Return on Capital Employed at 42.7% in Q1 2026, 69.14% in Q4 2025, and 113.07% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Omeros | 739.31 Mn | 739.31 Mn | 9.31 Mn | -42.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.70% |
| Dec 31, 2025 | -69.14% |
| Sep 30, 2025 | -113.07% |
| Jun 30, 2025 | -102.81% |
| Mar 31, 2025 | -94.21% |
| Dec 31, 2024 | -77.41% |
| Sep 30, 2024 | -62.09% |
| Jun 30, 2024 | -55.16% |
| Mar 31, 2024 | -48.12% |
| Dec 31, 2023 | -43.03% |
| Sep 30, 2023 | -45.42% |
| Jun 30, 2023 | -41.85% |
| Mar 31, 2023 | -37.60% |
| Dec 31, 2022 | -42.12% |
| Sep 30, 2022 | -45.88% |
| Jun 30, 2022 | -48.66% |
| Mar 31, 2022 | -45.48% |
| Dec 31, 2021 | -79.07% |
| Sep 30, 2021 | -179.65% |
| Jun 30, 2021 | -142.02% |